Completed PHASE2 INTERVENTIONAL NCT00501384

Satavaptan Dose-Ranging Study in the Prevention of Ascites (SPA)

Study for the Prevention of Ascites (SPA): Comparison of Fixed Doses of SR121463B Versus Placebo in the Reduction of Recurrence of Cirrhotic Ascites

Sponsor: Sanofi

Conditions Ascites Liver Cirrhosis

Interventions satavaptan (SR121463B)

Updated 8 times since 2017 Last updated: Jan 9, 2009 Started: Apr 30, 2004 Primary completion: May 31, 2005 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ascites and Liver Cirrhosis and is currently completed. Sanofi leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Berlin, Germany , Buenos Aires, Argentina , Cove, Australia , Diegem, Belgium , Laval, Canada , Milan, Italy , Paris, France , Prague, Czechia , Taipei, Taiwan and 1 more location